The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels

被引:61
|
作者
Mooradian, AD
Haas, MJ
Wong, NCW
机构
[1] St Louis Univ, Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab, St Louis, MO 63104 USA
[2] Univ Calgary, Dept Med & Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada
关键词
D O I
10.1210/er.2005-0013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One of the factors contributing to the increased risk of developing premature atherosclerosis is low plasma concentrations of high-density lipoprotein (HDL) cholesterol (HDLc). Multiple potential mechanisms account for the cardioprotective effects of HDL and its main protein apolipoprotein A-I (apo A-I). The low plasma concentrations of HDL could be the result of increased fractional clearance and reduced expression of apo A-I. To this end, nutrients play an important role in modulating the fractional clearance rate, as well as the rate of apo A-I gene expression. Because medical nutrition therapy constitutes the cornerstone of management of dyslipidemias, it is essential to understand the mechanisms underlying the changes in HDL level in response to alterations in dietary intake. In this review, we will discuss the effect of select nutrients on serum HDLc and apo A-I levels. Specifically, we will review the literature on the effect of carbohydrates, fatty acids, and ketones, as well as some of the nutrient-related metabolites, such as glucosamine and the prostanoids, on apo A-I gene expression. Because there are multiple mechanisms involved in the regulation of serum HDLc levels, changes in gene transcription do not necessarily correlate with clinical observations on serum levels of HDLc.
引用
收藏
页码:2 / 16
页数:15
相关论文
共 50 条
  • [1] The Effect of Nutritional Supplements on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I
    Mooradian, Arshag D.
    Haas, Michael J.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (04) : 253 - 274
  • [2] The Effect of Nutritional Supplements on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I
    Arshag D. Mooradian
    Michael J. Haas
    American Journal of Cardiovascular Drugs, 2014, 14 : 253 - 274
  • [3] Effect of simvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I in patients with elevated triglyceride blood levels
    Bays, H
    Mitchel, Y
    Mercuri, M
    DIABETES, 2001, 50 : A141 - A141
  • [4] APOLIPOPROTEIN A-I GENE RESTRICTION FRAGMENT LENGTH POLYMORPHISMS AND DECREASED LEVELS OF APOLIPOPROTEIN A-I AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN A PEDIGREE
    MATSAKIS, M
    WILE, DB
    WINDER, AF
    HUMPHRIES, SE
    ATHEROSCLEROSIS, 1988, 74 (03) : 252 - 253
  • [5] Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
    Kastelein, JJP
    Isaacsohn, JL
    Ose, L
    Hunninghake, DB
    Frohlich, J
    Davidson, MH
    Habib, R
    Dujovne, CA
    Crouse, JR
    Liu, MZ
    Melino, MR
    O'Grady, L
    Mercuri, M
    Mitchel, YB
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (02): : 221 - 223
  • [6] High-density lipoprotein subclasses and apolipoprotein A-I
    Duriez, P
    Fruchart, JC
    CLINICA CHIMICA ACTA, 1999, 286 (1-2) : 97 - 114
  • [7] MEASUREMENT OF HUMAN HIGH-DENSITY LIPOPROTEIN APOLIPOPROTEIN A-I IN SERUM BY RADIOIMMUNOASSAY
    KARLIN, JB
    JUHN, DJ
    STARR, JI
    SCANU, AM
    RUBENSTEIN, AH
    JOURNAL OF LIPID RESEARCH, 1976, 17 (01) : 30 - 37
  • [8] Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
    Crouse, JR
    Frohlich, J
    Ose, L
    Mercuri, M
    Tobert, JA
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (10): : 1476 - +
  • [9] Genetically Elevated Apolipoprotein A-I, High-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
    Haase, Christiane L.
    Tybjaerg-Hansen, Anne
    Grande, Peer
    Frikke-Schmidt, Ruth
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (12): : E500 - E510
  • [10] Twelve weeks of successful smoking cessation therapy with varenicline increases serum apolipoprotein a-I and high-density lipoprotein cholesterol levels
    Iwaoka, M.
    EUROPEAN HEART JOURNAL, 2014, 35 : 902 - 902